Abstract
The SARS-CoV-2 virus has been the subject of intense pharmacological research. Various pharmacotherapeutic approaches including antiviral and immunotherapy are being explored. A pandemic, however, cannot depend on the development of new drugs; the time required for conventional drug discovery and development is far too lengthy. As such, repurposing drugs is being used as a viable approach for identifying pharmacological agents for COVID-19 infections. Evaluation of repurposed drug candidates with pharmacogenomic analysis is being used to identify near-term pharmacological remedies for COVID-19.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Rohani N, Moughari FA, Eslahchi C et al (2021) Discovering potential candidates of RNAi-based therapy for COVID-19 using computational methods. PeerJ. https://doi.org/10.7717/peerj.10505
Depfenhart M, de Villiers D, Lemperle G et al (2020) Potential new treatment strategies for COVID-19: is there a role for bromhexine as add-on therapy? Intern Emerg Med 15:801–812
Loewy ZG (2020) The journey to a COVID-19 diagnostic test. J Precis Med 2020
Zhand S, Jazi MS, Mohammadi S et al (2020) COVID-19: the immune responses and Clinial therapy candidates. Int J Molec Sci. https://doi.org/10.3390/ijms21155559
Gavriatopoulou M, Ntanasis-Stathopoulos I, Korompoki E et al (2021) Emerging treatment strategies for COVID-19 infection. Clin Exp Med 21:167–179
Yang X, Liu Y, Yang Q et al (2020) Medication therapy strategies for the coronavirus disease 2019 (COVID-19): recent progress and challenges. Expert Rev Clin Pharm 13(9):957–975
Zhang J, Xie B, Hashimoto K (2020) Current status of potential therapeutic candidates for the COVID-19 crisis. Brain Behav Imm 87:59–73
Parvathaneni V, Gupta V (2020) Utilizing drug repurposing against COVID-19 – efficacy, limitations, and T challenges. Life Sci. https://doi.org/10.1016/j.lfs.2020.118275
Rudrapal M, Khairnar SJ, Jadhav AG (2020) Drug repurposing (DR): an emerging approach in drug discovery. https://doi.org/10.5772/IntechOpen.93193
Badary OA (2021) Pharmacogenomics and COVID-19: clinical implications of human genome interactions with repurposed drugs. Pharm J 21:275–284
Cafiero C, Re A, Micera A et al (2020) Pharmacogenomics and pharmacogenetics: in Silico prediction of drug effects in treatments for novel coronavirus SARS-CoV2 disease. Pharm Pers Med 13:463–484
Babayeva M, Loewy Z (2020) Repurposing drugs for COVID-19: pharmacokinetics and pharmacogenomics of chloroquine and Hydroxychloroquine. Pharm Pers Med 13:531–542
Al-Eitan LN, Alahmad SZ (2021) Pharmacogenomics of genetic polymorphism within the genes responsible for SARS CoV-2 susceptibility and the drug-metabolising genes used in treatment. Rev Med Virol. https://doi.org/10.1002/rmv.2194
Liu J, Zhou Y, Liu S et al (2018) The co-existence of copy number variations (CNVs) and single nucleotide polymorphisms (SNPs) at a locus can result in distorted calculations of the significance in associating SNPs to disease. Hum Genet 137:553–567
Offit K (2011) Personalized medicine: new genomics, old lessons. Hum Genet 130:3–14
Zhang J, Chiodini R, Badr A et al (2011) The impact of next-generation sequencing on genomics. J Genet Genomics 38:95–109
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Bock, R., Babayeva, M., Loewy, Z.G. (2022). COVID-19 Pharmacotherapy: Drug Development, Repurposing of Drugs, and the Role of Pharmacogenomics. In: Yan, Q. (eds) Pharmacogenomics in Drug Discovery and Development. Methods in Molecular Biology, vol 2547. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-2573-6_8
Download citation
DOI: https://doi.org/10.1007/978-1-0716-2573-6_8
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-2572-9
Online ISBN: 978-1-0716-2573-6
eBook Packages: Springer Protocols